Statistically significant differences were observed between the non-SLN negative group and the non-SLN positive group in terms of HER-2 status (negative: 82.5% vs. 69.8%; positive: 16.9% vs. 29.4%, p < 0.05), the number of positive SLNs (> 2: 11.04% vs. 35.71%, p < 0.05), tumor size (> 2 cm: 60.39% vs. 74.60%, p < 0.05), and lymphovascular invasion (32.47% vs. 74.60%, p < 0.05). This evidence concerns the gene ERBB2 and neoplasm.